These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Astilbin suppresses acute heart allograft rejection by inhibiting maturation and function of dendritic cells in mice.
    Author: Zou S, Shen X, Tang Y, Fu Z, Zheng Q, Wang Q.
    Journal: Transplant Proc; 2010 Nov; 42(9):3798-802. PubMed ID: 21094859.
    Abstract:
    The effect of astilbin on acute graft rejection was investigated in C57BL/6 mice carrying BALB/c hearts heterotopically transplanted into the neck vessels. Daily treatment with astilbin (50, 125, or 250 mg/kg intraperitoneally) significantly prolonged the survival of grafts in a dose-dependent manner, when cyclosporine (CsA; 5 mg/kg) was co-administered with astilbin (250 mg/kg), there was more potent immunosuppression than that solely achieved by 20 mg/kg CsA. Addition of 10 mg/mL astilbin significantly inhibited the proliferation and activation of T cells, as determined by (3)H-thymidine deoxyribose uptake, Western blots for nuclear factor κB and p38, and 1-way mixed lymphocyte reactions (MLR). Mature and antigen-presenting functions of dendritic cells (DCs) also were inhibited by astilbin (10 mg/mL), as determined by morphologic observations, flow cytometry, and MLR. These observations suggested that astilbin is a potential candidate for immunosuppressive therapy after heart engraftment. Inhibiting the maturation and antigen-presenting function of DCs and thus preventing T-cells activation is a possible mechanism underlying its inhibitory effects on acute heart allograft rejection.
    [Abstract] [Full Text] [Related] [New Search]